HK Grey Market | Metis TechBio Soars 191%; Impact Therapeutics Jumps 41%

Tiger Newspress
05/12

Metis TechBio, one of the "Top Three AI Drug Discovery" companies in Mainland China, soared 191% in Hong Kong’s grey market trading.

Founded in 2020, Metis TechBio focuses on the delivery and application of payloads across a range of biological systems, using artificial intelligence-powered nanotechnology to advance healthcare solutions.

Chinese cancer-drug developer Impact Therapeutics jumped 41% in Hong Kong’s grey market trading.

Founded in 2009, Impact Therapeutics is a commercial-stage biotechnology company focused on advancing synthetic lethality (SL)-based precision anti-cancer therapies globally, delivering innovative treatments to address the unmet medical needs of cancer patients.

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10